The Gly389 allele significantly increased the risk of heart failure by 10% in East Asians, while in whites, it trended to decrease the risk of HF (RR 0.94; 95% CI: 0.89–1.00; P = 0.06).
Meta-Analysis (n=7,000)
Does beta1 adrenergic receptor polymorphism status affect susceptibility to heart failure, response to beta-blocker therapy, and prognosis in patients with heart failure?
The Arg389Gly polymorphism is associated with differential LVEF improvement in response to beta-blocker therapy in heart failure patients, but does not independently predict overall prognosis.
Estimación del efecto: RR 1.10 (95% CI 1.01–1.19)
valor p: p=0.03
Based on our meta-analysis, the Gly389 allele and Gly389 homozygotes were risk factors in East Asians while trending to protect whites against HF. Furthermore, Arg389 homozygote is significantly associated with a favorable response to β-blocker treatment in HF patients. However, neither of the two polymorphisms is an independent predictor of the prognosis of HF.
Liu et al. (Tue,) conducted a meta-analysis in Heart Failure (n=7,000). b1 Adrenergic Receptor Polymorphisms vs. Control subjects with no b1 adrenergic receptor polymorphisms was evaluated on Risk of Heart Failure (HF) (RR 1.10, 95% CI 1.01–1.19, p=0.03). The Gly389 allele significantly increased the risk of heart failure by 10% in East Asians, while in whites, it trended to decrease the risk of HF (RR 0.94; 95% CI: 0.89–1.00; P = 0.06).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: